The US pharmaceutical and biotechnology sector faces significant reliance on Chinese sources, posing vulnerability to supply chain risks from abroad. Notably, Heparin, a crucial blood thinner, heavily relies on Chinese supplies, with about 70% of the US drug supply originating from China. The absence of any major American-owned producer for Heparin APIs exacerbates this dependence.
In the past, contaminated Chinese Heparin led to the deaths of at least 149 Americans in 2007 and 2008, underscoring the risks associated with this dependency. Despite these tragedies, little has changed, and current supply shortages are prompting US companies to exit Heparin production. This trend of decreasing production sources heightens the US’s vulnerability to disruptions in the Chinese supply chain.
An analysis of China’s 15th Five-Year Plan reveals Beijing’s efforts to strengthen its control over critical supply chains, including pharmaceuticals. China’s dominance in various sectors, coupled with its strategic maneuvers, poses challenges for global trade partners. The article warns of potential consequences, such as disruptions in Heparin supplies, which could have severe impacts on patients relying on the drug for medical treatments.
The US government’s initiative to establish a Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) in August 2025 aims to mitigate risks by stockpiling essential drug components. However, challenges persist, as certain critical drugs like Heparin, derived from animal tissue, cannot be produced using the technology employed by the flagship federal program. This underscores the complexities in ensuring pharmaceutical resilience amid supply chain vulnerabilities.
